

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY
U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

AstraZeneca Ref.: A2293-1P US

As a below named inventor, I hereby declare that:

Lilian ALCARAZ, Moya CAFFREY, Mark FURBER, Timothy LUKER, Michael MORTIMORE, Austen PIMM, Philip THORNE, and Paul WILLIS

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ADAMANTANE DERIVATIVES

The specification of which:

is attached hereto; or

was filed as United States application Serial No. ____ on ____ and was amended on ____ (if applicable); or

was filed as PCT international application Number PCT/SE00/02505 on December 12, 2000 and was amended under PCT Article 19

On ____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate or Section 365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign applications(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

PRIOR FOREIGN APPLICATION(S):

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
Sweden	9904651-8	17 December 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Great Britain	0015744.6	27 June 2000	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Great Britain	0017942.4	22 July 2000	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

Combined Declaration for Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

AstraZeneca Ref.: A2293-1P US

I hereby claim the benefits under Title 35, United States Code Section 119(e) of any United States provisional application(s) listed below.

U.S. PROVISIONAL APPLICATIONS

U.S. PROVISIONAL APPLICATION NO. **U.S. FILING DATE:**

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S.
FOR BENEFIT:**

U.S. OR PCT INTERNATIONAL APPLICATIONS		STATUS (Check One)		
APPLICATION NO.	FILING DATE	PATENTED	PENDING	ABANDONED
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

POWER OF ATTORNEY: As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 09629

Direct Telephone Calls To: Donald J. Bird (202) 739-5320

202-739-3000

Combined Declaration for Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

AstraZeneca Ref.: A2293-1P US


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	Lilian ALCARAZ	
RESIDENCE & CITIZENSHIP	Loughborough, Great Britain	COUNTRY OF CITIZENSHIP France
POST OFFICE ADDRESS	AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leisc. LE11 5RH, Great Britain	
FIRST OR SOLE INVENTOR'S SIGNATURE	DATE <i>13/05/02</i>	
FULL NAME OF SECOND INVENTOR	Moya CAFFREY	
RESIDENCE & CITIZENSHIP	Loughborough, Great Britain	COUNTRY OF CITIZENSHIP United Kingdom
POST OFFICE ADDRESS	AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leisc. LE11 5RH, Great Britain	
SECOND INVENTOR'S SIGNATURE	DATE <i>Moya Caffrey</i> <i>13/05/02</i>	
FULL NAME OF THIRD INVENTOR	Mark FURBER	
RESIDENCE & CITIZENSHIP	Loughborough, Great Britain	COUNTRY OF CITIZENSHIP United Kingdom
POST OFFICE ADDRESS	AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leisc. LE11 5RH, Great Britain	
THIRD INVENTOR'S SIGNATURE	DATE <i>M. Fieber</i> <i>7/5/02</i>	

Listing of Inventors Continued on attached page(s): Yes No

Combined Declaration for Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)


AstraZeneca Ref.: A2293-1P US

Combined Declaration for Patent Application and Power of Attorney - (Continued) (includes Reference to PCT International Applications)		
AstraZeneca Ref.: A2293-1P US		
FULL NAME OF FOURTH INVENTOR	Timothy LUKER	
RESIDENCE & CITIZENSHIP	Loughborough, Great Britain	COUNTRY OF CITIZENSHIP United Kingdom
POST OFFICE ADDRESS	AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leisc. LE11 5RH, Great Britain	
FOURTH INVENTOR'S SIGNATURE 		DATE 13/5/02
FULL NAME OF FIFTH INVENTOR	Michael MORTIMORE	
RESIDENCE & CITIZENSHIP	Oxfordshire, Great Britain	COUNTRY OF CITIZENSHIP United Kingdom
POST OFFICE ADDRESS	Vertex Pharmaceuticals Ltd., 88 Milton Park Abindgon, Oxfordshire OX14 4RY, Great Britain	
FIFTH INVENTOR'S SIGNATURE 		DATE 16/5/02
FULL NAME OF SIXTH INVENTOR	Austen PIMM	
RESIDENCE & CITIZENSHIP	Loughborough, Great Britain	COUNTRY OF CITIZENSHIP United Kingdom
POST OFFICE ADDRESS	AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leisc. LE11 5RH, Great Britain	
SIXTH INVENTOR'S SIGNATURE 		DATE 13/5/02

Listing of Inventors Continued on attached page(s): Yes No

Combined Declaration for Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

AstraZeneca Ref.: A2293-1P US

LL NAME OF SEVENTH INVENTOR	Philip THORNE	
RESIDENCE & CITIZENSHIP	Loughborough, Great Britain	COUNTRY OF CITIZENSHIP United Kingdom
POST OFFICE ADDRESS	AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leisc. LE11 5RH, Great Britain	
SEVENTH INVENTOR'S SIGNATURE	DATE  7/5/02	
FULL NAME OF EIGHT INVENTOR	Paul WILLIS	
RESIDENCE & CITIZENSHIP	Loughborough, Great Britain	COUNTRY OF CITIZENSHIP United Kingdom
POST OFFICE ADDRESS	AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leisc. LE11 5RH, Great Britain	
EIGHT INVENTOR'S SIGNATURE	DATE  13/5/2.	